Newsroom
About
Formed in 2012, the company is developing its proprietary smart-release therapies based on technologies originally developed at Tufts University and MIT. Vaxess is a venture-funded company that is also supported by the NIH and NSF.
Formed in 2012, the company is developing its proprietary smart-release therapies based on technologies originally developed at Tufts University and MIT. Vaxess is a venture-funded company that is also supported by the NIH and NSF.
Press Contacts
Media Gallery
Video
MIMIX Smart Release Technology - Vaxess Technologies
View on Youtube
Resources (Files)
Bios
Michael has spent his career transforming complex technologies into transformational products. Prior to Vaxess, Michael spent time at Google and Honda where he helped bring a range of products to market and earned more than fifteen patents. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard.
https://cdn.filestackcontent.com/NGSfLmfYSxCqYPlFNz9e
With a background in chemistry and nanomaterials, Kathryn has focused on the translation of academic research breakthroughs into impactful products, working across disciplines of biology, chemistry, and engineering. Prior to co-founding Vaxess, Kathryn was a postdoctoral research fellow in the Department of Chemistry & Chemical Biology at Harvard. Kathryn began her career in research and development at Merck. She holds a BA in chemistry from Colby College and a PhD in Physical Chemistry from Northwestern University.
https://cdn.filestackcontent.com/aWqc7oPQS3iWmyLH59OW
Dr. Fruehauf is the Co-Founder and General Partner of BioInnovation Capital. He is also a Founder and current President and Executive Director of LabCentral, a launchpad for high-potential biotech startups. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. Dr. Fruehauf is also a Co-Founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits.
https://cdn.filestackcontent.com/lR7YZRFAQLSGZzFc2XpH
Select Coverage
May 10, 2019
Bloomberg
Sep 12, 2019
Xconomy
